Default company panoramic image
Logo

Synbody Biotechnology, Inc. (SBI)

SBI utilizes proprietary protected disruptive technology to make superior products in the >$50B non-therapeutic market.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Farmington, CT, USA
  • Currency USD
  • Founded November 2010
  • Employees 5
  • Website synbodybio.com

Company Summary

SBI is harnessing a disruptive technology in the affinity ligand space, currently dominated by monoclonal antibodies. Our technology creates fully synthetic, high affinity/specificity ligands from small peptides with key advantages over antibodies. SBI’s business model generates rapid revenues in specific non-therapeutic markets, including agribusiness, diagnostics and bioprocessing, that are inadequately served by antibody technologies.

Team

Advisors

  • Default avatar
    Joanne Soslow (Morgan Lewis)
    Lawyer
    Unconfirmed
    Default avatar
    Fiondella, Milone & Lasaracina
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Connecticut Innovations
    Unconfirmed